ALZN Quote, Financials, Valuation and Earnings

BrightSpring Health Services, Inc. has a net margin of -- compared to Alzamend Neuro, Inc.'s net margin of 1.12%. Alzamend Neuro, Inc.'s return on equity of -140.8% beat BrightSpring Health Services, Inc.'s return on equity of 4.14%.

Alzamend Neuro, Inc. has a consensus price target of $28.00, signalling upside risk potential of 1250.5%. On the other hand BrightSpring Health Services, Inc. has an analysts' consensus of $41.93 which suggests that it could grow by 10.99%. Given that Alzamend Neuro, Inc. has higher upside potential than BrightSpring Health Services, Inc., analysts believe Alzamend Neuro, Inc. is more attractive than BrightSpring Health Services, Inc..

Alzamend Neuro, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BrightSpring Health Services, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Alzamend Neuro, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BrightSpring Health Services, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alzamend Neuro, Inc. pays -- of its earnings as a dividend. BrightSpring Health Services, Inc. pays out -- of its earnings as a dividend.

Alzamend Neuro, Inc. quarterly revenues are --, which are smaller than BrightSpring Health Services, Inc. quarterly revenues of $3.3B. Alzamend Neuro, Inc.'s net income of -$1M is lower than BrightSpring Health Services, Inc.'s net income of $37.5M. Notably, Alzamend Neuro, Inc.'s price-to-earnings ratio is -- while BrightSpring Health Services, Inc.'s PE ratio is 63.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alzamend Neuro, Inc. is -- versus 0.66x for BrightSpring Health Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI Corp. has a net margin of -- compared to Alzamend Neuro, Inc.'s net margin of --. Alzamend Neuro, Inc.'s return on equity of -140.8% beat CEL-SCI Corp.'s return on equity of -266.61%.

Alzamend Neuro, Inc. has a consensus price target of $28.00, signalling upside risk potential of 1250.5%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 808.12%. Given that Alzamend Neuro, Inc. has higher upside potential than CEL-SCI Corp., analysts believe Alzamend Neuro, Inc. is more attractive than CEL-SCI Corp..

Alzamend Neuro, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Alzamend Neuro, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alzamend Neuro, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Alzamend Neuro, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Alzamend Neuro, Inc.'s net income of -$1M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Alzamend Neuro, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alzamend Neuro, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Embecta Corp. has a net margin of -- compared to Alzamend Neuro, Inc.'s net margin of 10%. Alzamend Neuro, Inc.'s return on equity of -140.8% beat Embecta Corp.'s return on equity of --.

Alzamend Neuro, Inc. has a consensus price target of $28.00, signalling upside risk potential of 1250.5%. On the other hand Embecta Corp. has an analysts' consensus of $16.67 which suggests that it could grow by 37.97%. Given that Alzamend Neuro, Inc. has higher upside potential than Embecta Corp., analysts believe Alzamend Neuro, Inc. is more attractive than Embecta Corp..

Alzamend Neuro, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Embecta Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Alzamend Neuro, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Embecta Corp. offers a yield of 4.97% to investors and pays a quarterly dividend of $0.15 per share. Alzamend Neuro, Inc. pays -- of its earnings as a dividend. Embecta Corp. pays out 37.05% of its earnings as a dividend. Embecta Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alzamend Neuro, Inc. quarterly revenues are --, which are smaller than Embecta Corp. quarterly revenues of $264M. Alzamend Neuro, Inc.'s net income of -$1M is lower than Embecta Corp.'s net income of $26.4M. Notably, Alzamend Neuro, Inc.'s price-to-earnings ratio is -- while Embecta Corp.'s PE ratio is 7.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alzamend Neuro, Inc. is -- versus 0.66x for Embecta Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Medpace Holdings, Inc. has a net margin of -- compared to Alzamend Neuro, Inc.'s net margin of 16.84%. Alzamend Neuro, Inc.'s return on equity of -140.8% beat Medpace Holdings, Inc.'s return on equity of 78.26%.

Alzamend Neuro, Inc. has a consensus price target of $28.00, signalling upside risk potential of 1250.5%. On the other hand Medpace Holdings, Inc. has an analysts' consensus of $541.92 which suggests that it could fall by -5.24%. Given that Alzamend Neuro, Inc. has higher upside potential than Medpace Holdings, Inc., analysts believe Alzamend Neuro, Inc. is more attractive than Medpace Holdings, Inc..

Alzamend Neuro, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Medpace Holdings, Inc. has a beta of 1.427, suggesting its more volatile than the S&P 500 by 42.743%.

Alzamend Neuro, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medpace Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alzamend Neuro, Inc. pays -- of its earnings as a dividend. Medpace Holdings, Inc. pays out -- of its earnings as a dividend.

Alzamend Neuro, Inc. quarterly revenues are --, which are smaller than Medpace Holdings, Inc. quarterly revenues of $659.9M. Alzamend Neuro, Inc.'s net income of -$1M is lower than Medpace Holdings, Inc.'s net income of $111.1M. Notably, Alzamend Neuro, Inc.'s price-to-earnings ratio is -- while Medpace Holdings, Inc.'s PE ratio is 39.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alzamend Neuro, Inc. is -- versus 7.34x for Medpace Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.